Hybio Pharmaceutical Co., Ltd. (300199.SZ)
CNY 13.0
(4.17%)
CNY 13.0
(4.17%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 3.27 Billion CNY | -9.25% |
| 2022 | 3.61 Billion CNY | -7.56% |
| 2021 | 3.9 Billion CNY | -2.83% |
| 2020 | 4.02 Billion CNY | -14.91% |
| 2019 | 4.72 Billion CNY | -16.53% |
| 2018 | 5.66 Billion CNY | 6.84% |
| 2017 | 5.29 Billion CNY | 18.87% |
| 2016 | 4.45 Billion CNY | 25.69% |
| 2015 | 3.54 Billion CNY | 108.9% |
| 2014 | 1.69 Billion CNY | 31.72% |
| 2013 | 1.28 Billion CNY | 14.71% |
| 2012 | 1.12 Billion CNY | 8.48% |
| 2011 | 1.03 Billion CNY | 386.48% |
| 2010 | 212.88 Million CNY | 16.67% |
| 2009 | 182.47 Million CNY | 33.63% |
| 2008 | 136.55 Million CNY | 134.46% |
| 2007 | 58.23 Million CNY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 3.11 Billion CNY | 2.88% |
| 2024 Q1 | 2.99 Billion CNY | -8.74% |
| 2024 Q2 | 3.02 Billion CNY | 1.31% |
| 2023 Q2 | 3.49 Billion CNY | -2.41% |
| 2023 Q3 | 3.29 Billion CNY | -5.84% |
| 2023 FY | 3.27 Billion CNY | -9.25% |
| 2023 Q4 | 3.27 Billion CNY | -0.43% |
| 2023 Q1 | 3.58 Billion CNY | -0.82% |
| 2022 Q1 | 3.77 Billion CNY | -3.28% |
| 2022 Q4 | 3.61 Billion CNY | -2.85% |
| 2022 Q2 | 3.77 Billion CNY | -0.14% |
| 2022 FY | 3.61 Billion CNY | -7.56% |
| 2022 Q3 | 3.71 Billion CNY | -1.48% |
| 2021 Q3 | 3.82 Billion CNY | -1.5% |
| 2021 Q1 | 4.31 Billion CNY | 7.39% |
| 2021 Q2 | 3.88 Billion CNY | -9.97% |
| 2021 FY | 3.9 Billion CNY | -2.83% |
| 2021 Q4 | 3.9 Billion CNY | 2.04% |
| 2020 Q4 | 4.02 Billion CNY | -14.88% |
| 2020 FY | 4.02 Billion CNY | -14.91% |
| 2020 Q1 | 4.73 Billion CNY | 0.19% |
| 2020 Q2 | 4.7 Billion CNY | -0.61% |
| 2020 Q3 | 4.72 Billion CNY | 0.38% |
| 2019 FY | 4.72 Billion CNY | -16.53% |
| 2019 Q1 | 5.46 Billion CNY | -3.52% |
| 2019 Q2 | 5.74 Billion CNY | 5.17% |
| 2019 Q3 | 5.63 Billion CNY | -1.97% |
| 2019 Q4 | 4.72 Billion CNY | -16.08% |
| 2018 Q4 | 5.66 Billion CNY | -3.28% |
| 2018 FY | 5.66 Billion CNY | 6.84% |
| 2018 Q3 | 5.85 Billion CNY | 4.37% |
| 2018 Q2 | 5.6 Billion CNY | -4.54% |
| 2018 Q1 | 5.87 Billion CNY | 10.87% |
| 2017 Q2 | 4.6 Billion CNY | 2.91% |
| 2017 Q1 | 4.47 Billion CNY | 0.36% |
| 2017 FY | 5.29 Billion CNY | 18.87% |
| 2017 Q4 | 5.29 Billion CNY | 10.22% |
| 2017 Q3 | 4.8 Billion CNY | 4.42% |
| 2016 FY | 4.45 Billion CNY | 25.69% |
| 2016 Q2 | 3.79 Billion CNY | 3.57% |
| 2016 Q1 | 3.66 Billion CNY | 3.24% |
| 2016 Q3 | 4.51 Billion CNY | 19.13% |
| 2016 Q4 | 4.45 Billion CNY | -1.33% |
| 2015 Q3 | 3.19 Billion CNY | 4.76% |
| 2015 Q1 | 2.95 Billion CNY | 74.31% |
| 2015 FY | 3.54 Billion CNY | 108.9% |
| 2015 Q4 | 3.54 Billion CNY | 10.96% |
| 2015 Q2 | 3.05 Billion CNY | 3.1% |
| 2014 Q3 | 1.58 Billion CNY | 2.6% |
| 2014 FY | 1.69 Billion CNY | 31.72% |
| 2014 Q1 | 1.29 Billion CNY | 0.78% |
| 2014 Q4 | 1.69 Billion CNY | 7.43% |
| 2014 Q2 | 1.54 Billion CNY | 18.59% |
| 2013 Q2 | 1.13 Billion CNY | 1.24% |
| 2013 FY | 1.28 Billion CNY | 14.71% |
| 2013 Q4 | 1.28 Billion CNY | 8.57% |
| 2013 Q3 | 1.18 Billion CNY | 4.7% |
| 2013 Q1 | 1.11 Billion CNY | -0.34% |
| 2012 Q4 | 1.12 Billion CNY | 5.91% |
| 2012 FY | 1.12 Billion CNY | 8.48% |
| 2012 Q1 | 1.05 Billion CNY | 2.02% |
| 2012 Q2 | 1.03 Billion CNY | -1.95% |
| 2012 Q3 | 1.06 Billion CNY | 2.39% |
| 2011 Q4 | 1.03 Billion CNY | 3.64% |
| 2011 Q2 | 969.03 Million CNY | 1.94% |
| 2011 Q1 | 950.63 Million CNY | 346.55% |
| 2011 Q3 | 999.31 Million CNY | 3.12% |
| 2011 FY | 1.03 Billion CNY | 386.48% |
| 2010 Q2 | 199.88 Million CNY | 0.0% |
| 2010 FY | 212.88 Million CNY | 16.67% |
| 2010 Q4 | 212.88 Million CNY | 0.0% |
| 2009 FY | 182.47 Million CNY | 33.63% |
| 2008 FY | 136.55 Million CNY | 134.46% |
| 2007 FY | 58.23 Million CNY | 0.0% |